Santhera的AGAMREE在香港获批准 治疗杜尚症肌肉萎缩症 Santhera's AGAMREE gets approval in Hong Kong for treating Duchenne Muscular Dystrophy.

Santhera制药公司在香港获批AGAMREE(瓦莫罗酮)治疗Duchenne肌肉萎缩症,这是一种罕见的遗传障碍,造成肌肉虚弱和丧失。 Santhera Pharmaceuticals has received approval in Hong Kong for AGAMREE (Vamorolone) to treat Duchenne Muscular Dystrophy, a rare genetic disorder causing muscle weakness and loss. 这一批准标志着在使全球更多患者获得治疗方面迈出了重要一步。 This approval marks a significant step in making the treatment accessible to more patients globally.